Innoviva Specialty Therapeutics to present antibiotic data at IDWeek 2026
INVA•Innoviva Specialty Therapeutics will present four abstracts at IDWeek 2026, scheduled for October 21-24 in Washington, D.C. Three posters will cover ceftobiprole, including pediatric use, and an oral presentation will examine zoliflodacin treatment of urogenital gonorrhea in patients co-infected with chlamydia.
1. Four abstracts planned
Innoviva subsidiary Innoviva Specialty Therapeutics will present four abstracts at IDWeek 2026, running October 21-24 in Washington, D.C. Three ceftobiprole (Zevtera) posters will cover activity against contemporary U.S. clinical isolates and pediatric use, with presentations scheduled for October 22 and 24.
2. Oral presentation
An October 24 oral presentation will examine zoliflodacin (Nuzolvence) eradication of urogenital gonorrhea in patients co-infected with chlamydia.
